Vaccination During Upper Respiratory Tract Infection
Yes, it is generally safe to receive both influenza and COVID-19 vaccines while experiencing a mild upper respiratory tract infection (URTI), though the decision depends on illness severity.
Key Considerations
Mild vs. Moderate-to-Severe Illness
The primary determining factor is whether your URTI is mild or more severe:
Mild illness (runny nose, sore throat, mild cough without fever): Vaccination can proceed safely. There are no contraindications to receiving inactivated influenza vaccines or COVID-19 vaccines with minor upper respiratory symptoms 1.
Moderate-to-severe illness with fever: It is prudent to defer vaccination until symptoms improve. This recommendation exists primarily to avoid confusing vaccine side effects with worsening illness symptoms, not because of safety concerns.
Vaccine Compatibility and Co-administration
Inactivated influenza vaccines (IIV) and COVID-19 vaccines can be administered simultaneously or sequentially without safety concerns 1. The 2024-25 ACIP guidelines explicitly state that IIVs can be given concomitantly with other inactivated or live vaccines at separate anatomic sites 1.
Recent research strongly supports co-administration safety:
- A 2026 study of very old adults (mean age 84.3 years) with substantial multimorbidity found that same-day influenza and COVID-19 vaccination was well tolerated, with 44.4% reporting at least one adverse event, most mild, and no participants developing fever at 48 hours 2.
- Multiple studies demonstrate that co-administration does not substantially increase adverse events compared to single vaccine administration 3, 4.
Practical Algorithm
If you have:
- Only mild URTI symptoms (no fever, able to perform daily activities): Proceed with vaccination
- Fever >38°C (100.4°F) or moderate-to-severe symptoms: Defer vaccination until symptoms resolve or improve significantly
- Uncertainty about severity: Measure temperature; if <38°C and symptoms don't prevent daily activities, proceed
Important Caveats
Live attenuated influenza vaccine (LAIV, nasal spray): Different considerations may apply, though the evidence provided focuses on inactivated vaccines 1.
Distinguishing vaccine reactions from illness progression: If you proceed with vaccination during mild URTI, be aware that it may be difficult to distinguish between worsening illness and vaccine side effects in the 24-48 hours post-vaccination.
Immunocompromised status: If you have significant immunosuppression, consult your healthcare provider, as timing recommendations may differ 5.
Expected Reactions with Co-administration
When receiving both vaccines together, local reactions are more common at the COVID-19 injection site than the influenza site 2. Higher comorbidity burden and prior COVID-19 infection predict increased adverse events 2. Most reactions are mild and resolve within 4 days 1.
The evidence strongly supports that mild URTI does not pose a safety risk for vaccination, and co-administration of influenza and COVID-19 vaccines is both safe and effective 1, 2, 3, 4.